Abstract
There is concern that variola virus, the aetiological agent of smallpox, may be used as a biological weapon. For this reason several countries are now stockpiling (vaccinia virus-based) smallpox vaccine. Although the preventive use of smallpox vaccination has been well documented, little is known about its efficacy when used after exposure to the virus. Here we compare the effectiveness of (1) post-exposure smallpox vaccination and (2) antiviral treatment with either cidofovir (also called HPMPC or Vistide) or with a related acyclic nucleoside phosphonate analogue (HPMPO–DAPy) after lethal intratracheal infection of cynomolgus monkeys (Macaca fascicularis) with monkeypox virus (MPXV). MPXV causes a disease similar to human smallpox1 and this animal model can be used to measure differences in the protective efficacies of classical and new-generation candidate smallpox vaccines2. We show that initiation of antiviral treatment 24 h after lethal intratracheal MPXV infection, using either of the antiviral agents and applying various systemic treatment regimens, resulted in significantly reduced mortality and reduced numbers of cutaneous monkeypox lesions. In contrast, when monkeys were vaccinated 24 h after MPXV infection, using a standard human dose of a currently recommended smallpox vaccine (Elstree-RIVM), no significant reduction in mortality was observed. When antiviral therapy was terminated 13 days after infection, all surviving animals had virus-specific serum antibodies and antiviral T lymphocytes. These data show that adequate preparedness for a biological threat involving smallpox should include the possibility of treating exposed individuals with antiviral compounds such as cidofovir or other selective anti-poxvirus drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zaucha, G. M., Jahrling, P. B., Geisbert, T. W., Swearengen, J. R. & Hensley, L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 81, 1581–1600 (2001)
Stittelaar, K. J. et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 79, 7845–7851 (2005)
Smith, G. L. & McFadden, G. Smallpox: anything to declare? Nature Rev. Immunol. 2, 521–527 (2002)
Breman, J. G. & Arita, I. The confirmation and maintenance of smallpox eradication. N. Engl. J. Med. 303, 1263–1273 (1980)
Lewis-Jones, S. Zoonotic poxvirus infections in humans. Curr. Opin. Infect. Dis. 17, 81–89 (2004)
Grabenstein, J. D. & Winkenwerder, W. Jr US military smallpox vaccination program experience. J. Am. Med. Assoc. 289, 3278–3282 (2003)
De Clercq, E. & Neyts, J. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. Rev. Med. Virol. 14, 289–300 (2004)
Finkel, E. Australia. Engineered mouse virus spurs bioweapon fears. Science 291, 585 (2001)
Stanford, M. M. & McFadden, G. The ‘supervirus’? Lessons from IL-4-expressing poxviruses. Trends Immunol. 26, 339–345 (2005)
Bray, M. & Roy, C. J. Antiviral prophylaxis of smallpox. J. Antimicrob. Chemother. 54, 1–5 (2004)
Buller, R. M. et al. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318, 474–481 (2004)
Quenelle, D. C., Collins, D. J. & Kern, E. R. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother. 47, 3275–3280 (2003)
Roy, C. J., Baker, R., Washburn, K. & Bray, M. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge. Antimicrob. Agents Chemother. 47, 2933–2937 (2003)
Smee, D. F., Bailey, K. W. & Sidwell, R. W. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice. Chemotherapy 49, 126–131 (2003)
Neyts, J., Leyssen, P., Verbeken, E. & De Clercq, E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob. Agents Chemother. 48, 2267–2273 (2004)
Smee, D. F., Bailey, K. W., Wong, M. H., Wandersee, M. K. & Sidwell, R. W. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J. Infect. Dis. 190, 1132–1139 (2004)
De Clercq, E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 23, 456–458 (2002)
Bronze, M. S. & Greenfield, R. A. Therapeutic options for diseases due to potential viral agents of bioterrorism. Curr. Opin. Investig. Drugs 4, 172–178 (2003)
Prichard, M. N. & Kern, E. R. Orthopoxvirus targets for the development of antiviral therapies. Curr. Drug Targets Infect. Disord. 5, 17–28 (2005)
Wharton, M. et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm. Rep. 52, 1–16 (2003)
Yang, G. et al. An orally bioavailable anti-poxvirus compound (ST-246) that inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79, 13139–13149 (2005)
Reeves, P. M. et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature Med. 11, 731–739 (2005)
Yang, H. et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 115, 379–387 (2005)
McFadden, G. Gleevec casts a pox on poxviruses. Nature Med. 11, 711–712 (2005)
Balzarini, J. et al. 6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity. Nucleosides Nucleotides Nucleic Acids 23, 1321–1327 (2004)
Neyts, J., Leyssen, P., De Clercq, E. & Holy, A. Effects of (S)-HPMPDAP and (S)-HPMPO-DAPym on vaccinia virus infections in mice. Antiviral Res. 62, 109 (2004)
Rosenthal, S. R. & Clifford, J. C. Development of vaccines for bio-warfare agents. Dev. Biol. (Basel) 110, 99–105 (2002)
Massoudi, M. S., Barker, L. & Schwartz, B. Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis. J. Infect. Dis. 188, 973–976 (2003)
Cundy, K. C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36, 127–143 (1999)
Meyer, H. et al. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. J. Clin. Microbiol. 40, 2919–2921 (2002)
Acknowledgements
We are grateful to F. Pistoor, J. Rimmelzwaan-Offutt, S. Slabbekoorn-Romijn, R. D. d'Ullois and J. Guldemeester for assistance and to R. Gruters for comments. This work in Leuven and Prague was supported by an NIAID/NIH grant to J.N. and A.H.. This study is a part of an IOCB (Prague) research programme and project.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The Department of Virology and ViroClinics BV are involved in performing monkeypox virus challenge experiments for Bavarian Nordic GmbH (Martinsried, Germany), supported by the National Institutes of Health (NIH).
Supplementary information
Supplementary Notes
This file contains Supplementary Methods, the Supplementary Figure Legend and additional references. (DOC 38 kb)
Supplementary Figure 1
Development of poxvirus-specific IgG antibodies in 1/100-diluted plasma samples of all the monkeys treated as described for Fig.1 (main text). (PDF 16 kb)
Rights and permissions
About this article
Cite this article
Stittelaar, K., Neyts, J., Naesens, L. et al. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 439, 745–748 (2006). https://doi.org/10.1038/nature04295
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature04295
This article is cited by
-
Potential use of cidofovir, brincidofovir, and tecovirimat drugs in fighting monkeypox infection: recent trends and advancements
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
-
Mpox (formerly monkeypox): pathogenesis, prevention, and treatment
Signal Transduction and Targeted Therapy (2023)
-
Mpox and HIV: a Narrative Review
Current HIV/AIDS Reports (2023)
-
Exploring Monkeypox: prospects for therapeutics through computational-aided drug discovery
Molecular Diversity (2023)
-
Mpox: Special Considerations in the Immunocompromised Host
Current Treatment Options in Infectious Diseases (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.